Advertisement


Greg D. Judy, MD, on Safety Incidents in Radiotherapy

2017 Quality Care Symposium

Advertisement

Greg D. Judy, MD, of UNC Health Care, discusses the contributing factors, and possible fixes, for near-miss and actual safety incidents in patients being treated with radiotherapy.



Related Videos

Breast Cancer
Prostate Cancer
Issues in Oncology

Diana D. Jeffery, PhD, on Mental Health Comorbidities: Predictors of Cost and Utilization

Diana D. Jeffery, PhD, of the Defense Health Agency, discusses the need to screen for mental health comorbidities, including depression, anxiety, adjustment disorders, substance use disorders, and persistent mental illnesses, as shown in a study of breast and prostate cancer patients (Abstract 18).

Issues in Oncology

Gwendolyn P. Quinn, PhD, on Underserved Cancer Patients and Survivors: Are We Listening to Them?

Gwendolyn P. Quinn, PhD, of Moffitt Cancer Center, discusses the challenges that minority, LGBTQ, low-literacy, and underserved populations face in getting their voices heard and what it will take to change that.

Issues in Oncology

Julie Bryar Porter, MS, on Improving Care: One Center’s Experience

Julie Bryar Porter, MS, of Stanford Health Care, discusses an approach to improving patient care with physician-led quality measures from diagnosis through end of life implemented at her academic cancer center (Abstract 49).

Breast Cancer
Survivorship

Nicole Mittmann, PhD, on Breast Cancer Well Follow-up

Nicole Mittmann, PhD, of the Sunnybrook Health Sciences Centre, discusses her study findings on transitioning breast cancer survivors to primary care and the savings in resources and dollars that accrued as a result (Abstract 1).

Issues in Oncology
Lung Cancer

Thomas J. Smith, MD, on Oral Abstract Session B (2017 Quality Care Symposium)

Thomas J. Smith, MD, of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, summarizes two papers for which he was a discussant: reducing overuse of colony-stimulating factors without compromising the safety of patients with lung cancer receiving chemotherapy, and a cost-and-survival analysis before and after implementing Dana-Farber Clinical Pathways for patients with stage IV non–small cell lung cancer (Abstracts 3, 52).

Advertisement

Advertisement




Advertisement